[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=aa3f7c261f763e1dfa95ba349aad86c0ab18ab35fdb97093ebba4523b1f45ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744753516,
      "headline": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
      "id": 133932721,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=aa3f7c261f763e1dfa95ba349aad86c0ab18ab35fdb97093ebba4523b1f45ce7"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth?",
    "summary": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big […]",
    "url": "https://finnhub.io/api/news?id=b6ff35210685ab0541e607e1b08b32dd0cc4e43c1ebbfd09d3d88c626e82b7aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744738597,
      "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth?",
      "id": 133927929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big […]",
      "url": "https://finnhub.io/api/news?id=b6ff35210685ab0541e607e1b08b32dd0cc4e43c1ebbfd09d3d88c626e82b7aa"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
    "summary": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
    "url": "https://finnhub.io/api/news?id=3331affb6c0b2bf193e2d253ab1303d26d95a032425f678a2e113d4054063d46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744736220,
      "headline": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
      "id": 133927930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
      "url": "https://finnhub.io/api/news?id=3331affb6c0b2bf193e2d253ab1303d26d95a032425f678a2e113d4054063d46"
    }
  },
  {
    "ts": null,
    "headline": "VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study",
    "summary": "Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.",
    "url": "https://finnhub.io/api/news?id=ba34d0e9e01b07024fe08b6cafea6fe346d4125ef3d9e36cc27f83c70f82bfab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744734420,
      "headline": "VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study",
      "id": 133927931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.",
      "url": "https://finnhub.io/api/news?id=ba34d0e9e01b07024fe08b6cafea6fe346d4125ef3d9e36cc27f83c70f82bfab"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market",
    "summary": "Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.",
    "url": "https://finnhub.io/api/news?id=f66e70cb2ce25d77f2724f8f6197654f1de5fe206e0af337fb60130dcbccc506",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744734098,
      "headline": "Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market",
      "id": 133928742,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304192083/image_1304192083.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=f66e70cb2ce25d77f2724f8f6197654f1de5fe206e0af337fb60130dcbccc506"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes",
    "summary": "Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX stock prospects.",
    "url": "https://finnhub.io/api/news?id=c30e1831f90d0e661f7f3fa680dba6ac78b39405ea2acc71e300a7cb47024298",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744727870,
      "headline": "Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes",
      "id": 133928198,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196950234/image_2196950234.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX stock prospects.",
      "url": "https://finnhub.io/api/news?id=c30e1831f90d0e661f7f3fa680dba6ac78b39405ea2acc71e300a7cb47024298"
    }
  },
  {
    "ts": null,
    "headline": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
    "summary": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the",
    "url": "https://finnhub.io/api/news?id=73010c01a9588a7879ce392276d2f3d43e16b84d650a5442faec5fb1ec7d0cea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744727725,
      "headline": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
      "id": 133922054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the",
      "url": "https://finnhub.io/api/news?id=73010c01a9588a7879ce392276d2f3d43e16b84d650a5442faec5fb1ec7d0cea"
    }
  },
  {
    "ts": null,
    "headline": "European pharma companies issue demands to stay in EU ahead of expected US tariffs",
    "summary": "PARIS -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on...",
    "url": "https://finnhub.io/api/news?id=4d1469be7fbdc5fca44c3ef5791634fe725d6e0f10b09b0c2aba120765688b66",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744727597,
      "headline": "European pharma companies issue demands to stay in EU ahead of expected US tariffs",
      "id": 133927492,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "PARIS -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on...",
      "url": "https://finnhub.io/api/news?id=4d1469be7fbdc5fca44c3ef5791634fe725d6e0f10b09b0c2aba120765688b66"
    }
  },
  {
    "ts": null,
    "headline": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
    "summary": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
    "url": "https://finnhub.io/api/news?id=54b748667207425b21b7ae1daf566df6e213627eb85f4a28aee70275a3aaa22a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744725600,
      "headline": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
      "id": 133922055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
      "url": "https://finnhub.io/api/news?id=54b748667207425b21b7ae1daf566df6e213627eb85f4a28aee70275a3aaa22a"
    }
  },
  {
    "ts": null,
    "headline": "Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke",
    "summary": "European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv",
    "url": "https://finnhub.io/api/news?id=ac9d9d893e3ba83e046d89f8de940bfbc853dbe11ac4da97030fc18fac9428b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744718921,
      "headline": "Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke",
      "id": 133922056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv",
      "url": "https://finnhub.io/api/news?id=ac9d9d893e3ba83e046d89f8de940bfbc853dbe11ac4da97030fc18fac9428b0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): One of the High Growth Forever Dividend Stocks to Invest In",
    "summary": "We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the past two years, largely due to […]",
    "url": "https://finnhub.io/api/news?id=1e8c3bc9d3609482690e1d09bd0bcce609667fdb093d1e414ff423fb235a5bca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744717684,
      "headline": "Eli Lilly and Company (LLY): One of the High Growth Forever Dividend Stocks to Invest In",
      "id": 133922057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the past two years, largely due to […]",
      "url": "https://finnhub.io/api/news?id=1e8c3bc9d3609482690e1d09bd0bcce609667fdb093d1e414ff423fb235a5bca"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves",
    "summary": "Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves",
    "url": "https://finnhub.io/api/news?id=f25f4c39a585d24493d2a420885960c433e9542707a4c81432b13092d254ab72",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744713792,
      "headline": "Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves",
      "id": 133921555,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f25f4c39a585d24493d2a420885960c433e9542707a4c81432b13092d254ab72"
    }
  },
  {
    "ts": null,
    "headline": "Tariff wars to hit popular US-made drugs in China, regulator data shows",
    "summary": "China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for higher duties.  The Trump administration is also currently investigating whether imports of pharmaceutical products threaten U.S. national security, which could be a precursor to slapping tariffs on those products.  Big pharmaceutical companies including AstraZeneca, Sanofi, GSK and Eli Lilly have at least one U.S. manufacturing site for their drugs sold in China, records from China's National Medical Products Administration showed.",
    "url": "https://finnhub.io/api/news?id=459e9604decf0732d26e1e90b9117502128a99daeb0a5ad368826f4dd1d2e7d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744709994,
      "headline": "Tariff wars to hit popular US-made drugs in China, regulator data shows",
      "id": 133922058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for higher duties.  The Trump administration is also currently investigating whether imports of pharmaceutical products threaten U.S. national security, which could be a precursor to slapping tariffs on those products.  Big pharmaceutical companies including AstraZeneca, Sanofi, GSK and Eli Lilly have at least one U.S. manufacturing site for their drugs sold in China, records from China's National Medical Products Administration showed.",
      "url": "https://finnhub.io/api/news?id=459e9604decf0732d26e1e90b9117502128a99daeb0a5ad368826f4dd1d2e7d6"
    }
  },
  {
    "ts": null,
    "headline": "PepsiCo's Valuation Hasn't Been This Low In A Decade - Time To Buy",
    "summary": "PepsiCo's Valuation Hasn't Been This Low In A Decade - Time To Buy",
    "url": "https://finnhub.io/api/news?id=a4b9377a33a8ef4c6882560a1c42e3c0503e447c0752d0733ec1fb4df18a4efb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744701300,
      "headline": "PepsiCo's Valuation Hasn't Been This Low In A Decade - Time To Buy",
      "id": 133920251,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a4b9377a33a8ef4c6882560a1c42e3c0503e447c0752d0733ec1fb4df18a4efb"
    }
  },
  {
    "ts": null,
    "headline": "Trump Initiates Chips and Drug Probes Ahead of More Tariffs",
    "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
    "url": "https://finnhub.io/api/news?id=795938dc3145a689055e139871037666a344686709a9ebbfb8180cb558a8c6b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744687957,
      "headline": "Trump Initiates Chips and Drug Probes Ahead of More Tariffs",
      "id": 133917679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
      "url": "https://finnhub.io/api/news?id=795938dc3145a689055e139871037666a344686709a9ebbfb8180cb558a8c6b7"
    }
  }
]